Praxis Medical Insights

Clinical Presentation and Diagnosis

The American College of Cardiology defines rhabdomyolysis as CK >10 times the upper limit of normal with evidence of renal injury, which is exceedingly rare with statin therapy and typically occurs in patients with multiple predisposing comorbidities and concomitant high-risk medications 1, 2, 3, 4
Severe muscle pain, tenderness, or weakness, often bilateral and involving proximal muscles, can be a symptom of rhabdomyolysis 1, 3
Generalized muscle aches and stiffness that are unexplained and severe can also be a symptom of rhabdomyolysis 5, 6
Muscle cramping and fatigue that is markedly worse than baseline can be a symptom of rhabdomyolysis 5, 6
Dark-colored urine indicating muscle breakdown can be a sign of rhabdomyolysis 5, 6
Unusual fatigue or weakness beyond typical muscle complaints can be a sign of rhabdomyolysis 5, 6
Signs of acute renal failure, such as decreased urine output, confusion, and nausea, can be a sign of rhabdomyolysis 1, 2

Prompt discontinuation of the statin and immediate evaluation for rhabdomyolysis with tests such as creatine kinase (CK) level, serum creatinine, and urinalysis for myoglobinuria are recommended 5, 6, 3
Monitoring renal function closely with serial creatinine measurements is crucial 5, 6

The American College of Cardiology recommends immediate statin discontinuation, aggressive IV hydration, and urgent evaluation for renal injury in cases of suspected rhabdomyolysis 1, 2, 5
Discontinuing the statin immediately upon recognition of severe symptoms is essential 1, 2, 5
Initiating aggressive IV hydration to prevent acute renal failure is crucial 5, 6
Monitoring renal function closely with serial creatinine measurements is recommended 5, 6
Evaluating for reversible causes, such as drug interactions, metabolic abnormalities, renal or hepatic dysfunction, and recent trauma or excessive physical activity, is necessary 1, 2, 4, 7

Patients who experience rhabdomyolysis may need to discontinue statin use indefinitely, although reversible causes should be sought 1, 2, 3
The 2018 ACC/AHA guidelines emphasize that rechallenge after true rhabdomyolysis carries significant risk 1, 2
Waiting at least 2 months to ensure complete resolution of symptoms and CK normalization before reconsidering statin therapy is recommended 7
Considering alternative lipid-lowering therapy, such as ezetimibe or PCSK9 inhibitors, as first-line options is suggested 7
Using a different statin at the lowest possible dose with extremely close monitoring is recommended if rechallenge is attempted 7
Pravastatin or rosuvastatin at low doses have lower myopathy risk profiles 7

Advanced age, especially >75-80 years, particularly in women, increases the risk of rhabdomyolysis 7
Small body frame and frailty increase the risk of rhabdomyolysis 7
Renal insufficiency, especially diabetic nephropathy, increases the risk of rhabdomyolysis 1
Polypharmacy and drug interactions increase the risk of rhabdomyolysis 7
Higher statin doses increase the risk of rhabdomyolysis 7
Asian ancestry increases the risk of rhabdomyolysis 4
Excessive alcohol use increases the risk of rhabdomyolysis 4